CD274 and neoplasm: While tumor expression of PD-L1 might be suggestive of a tumor that is subduing an immune response and as a result could serve as a potential biomarker for clinical benefit, it is clear that not all PD-L1-expressing tumors respond to PD-1/PD-L1 inhibitors.